I'm Barry Rithaltz, inviting you to join me for the Masters in Business podcast.
Every week we bring you fascinating conversations with the people who shape markets,
investing, and business.
CEOs, fund managers, billionaires, Nobel laureates, traders, analysts,
economists, everybody that affects what's going on in the market.
Whether you own stocks, bonds, real estate,
commodities, crypto, you really need to hear these conversations.
Sometimes it's behaviorists like Dick Thaler or Bob Schiller.
Sometimes it's fund managers like Peter Lynch, Bill Miller, Ray Dalio.
Sometimes it's authors Michael Lewis, author of The Big Short and Moneyball.
Regardless of the conversation, these are the folks that move markets each week.
That's the Masters in Business podcast with me, Barry Rithaltz.
Listen on Apple, Spotify, or wherever you get your podcasts.
It's been a little more than eight years since the FDA approved the medical use of semi-glutide.
That's the key ingredient in ozempic.
Since then, the market for diabetes and weight loss drugs has exploded.
300 percent, which is the increase in U.S.
sales of ozempic or similar medicines between 2020 and 2022.
The popularity of those drugs on social media and in clinics is soaring.
For years, the patent for in many countries has been held by one company, Novo Nordisk.